YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Cybin has delivered a 114.8% gain over the past year, which puts a spotlight on whether that kind of share price reset still lines up with what its balance sheet and book value suggest the stock is worth today. With the psychedelic mental…
Key Points Interested in Cybin Inc.? Here are five stocks we like better. Cybin, doing business as Helus Pharma, asked shareholders to approve changing the corporate name to Helus Pharma Inc. and setting the board at eight directors; both…
[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House advisor Heidi Overton as the agency's next…
Helus Pharma CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. NEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Hel…
* Cybin press release [https://seekingalpha.com/pr/20619592-helus-pharma-reports-first-quarter-fiscal-2027-financial-results-and-recent-business] (HELP [https://seekingalpha.com/symbol/HELP]): Q1 Net loss was $47.8 million for the quarter…
(RTTNews) - On Monday, Cybin D/B/A Helus Pharma (HELP) announced that it has appointed Michael Halstead as Chief Executive Officer, effective immediately. Halstead brings 25 years of industry experience, most recently serving as President…
Helus Pharma Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson Experienced executive with a proven track record of guiding pharmace…
Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, President and Chief Operations Offi…
We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Cybin D/B/A Helus Pharma (NASDAQ:HELP) is one of the best psychedelic stocks on our list. TheFly reported on July 1 that Canaccord analyst Sumant Ku…
[Psychedelic Brain Therapy] wildpixel/iStock via Getty Images * A memorandum of understanding brokered Monday between HHS and the Veterans Administration could bode well for companies developing psychedelic-based drug treatments. * The MOU…
(RTTNews) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which has revised its clinical data readout timeline, amon…
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergi…
(RTTNews) - Helus Pharma (HELP) reported strong clinical and financial momentum as the company announced that its Phase 3 APPROACH trial has surpassed 86% enrolment, while also pricing a US$50 million underwritten offering to support advan…
Helus Pharma (HELP [https://seekingalpha.com/symbol/HELP]) announced the pricing [https://seekingalpha.com/pr/20561856-helus-pharma-announces-us-50-million-underwritten-offering] of an underwritten public offering of 10.31M common shares,…
NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), please note references to Veterans Exploring Treatment Solutions (“VETS”)…
Helus Pharma Addition of globally recognized leaders in translational science and clinical development as the Company advances its pipeline towards key inflection points NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Helus Pharma…
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression. Continue Reading
[Heart Health Concept] Eoneren/E+ via Getty Images Psychedelic stocks surged in premarket trading on Monday after President Donald Trump signed an executive order on Saturday to dramatically accelerate research into, and expand patient acc…
Compass Pathways (CMPS) and other psychedelic shares were up in Monday premarket activity, after US PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
[Binary Code and stock market Data overlay for Financial Technology and Exchange] Stock index futures dipped lower Monday morning as renewed U.S.-Iran geopolitical tensions rattled global risk sentiment and drove oil prices higher. Here ar…
US stocks fell on Monday after a chaotic weekend of events reignited US-Iran tensions, putting peace talks at risk and leaving investors bracing for more uncertainty. The S&P 500 (^GSPC) shed 0.1%, while the tech-heavy Nasdaq Composite (^I…
[President Trump Signs Executive Order At The White House] Tasos Katopodis/Getty Images News President Donald Trump on Saturday signed an executive order to expedite access to research and treatments based on psychedelic drugs, a move tha…
Helus Pharma Dr. Kramer’s 25 years’ of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO, April 16, 2026 (GLOBE NE…
Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 points on top of Standard of Care (“SoC”) at 6 weeksDurable effects sustained through at least 6 monthsIn Phase 1…
Helus Pharma In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release constitutes a “designated news…
Cybin D/B/A Helus Pharma (NASDAQ:HELP) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds.Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers The seventh sto…
Helus Pharma Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7.35) versus placebo at two…
* Cybin press release [https://seekingalpha.com/pr/20399084-helus-pharma-reports-third-quarter-fiscal-year-2026-financial-results-and-recent-business] (HELP [https://seekingalpha.com/symbol/HELP]): Q3 GAAP EPS of -$1.00 misses by $0.41. MO…
Helus Pharma Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Me…
TORONTO, December 18, 2025--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treat…
TORONTO, December 18, 2025--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation trea…